About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex. The Company's Ad-RTS-IL-12 + veledimex has been evaluated in two Phase II studies, the first for the treatment of metastatic melanoma, and the second for the treatment of unresectable recurrent or metastatic breast cancer. It has initiated the Phase I study for malignant glioma. The Company has completed the Phase II monotherapy studies in melanoma and breast cancer using Ad-RTS-IL-12 + veledimex. It has initiated a Phase Ib/II study of Ad-RTS-hIL-12 + veledimex following chemotherapy for the treatment of patients with locally metastatic breast cancer. Its initial drug candidate being developed using the synthetic immuno-oncology platform is Ad-RTS-IL-12 + veledimex.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: ZIOP
- CUSIP: 98973P10
- Previous Close: $6.82
- 50 Day Moving Average: $6.12
- 200 Day Moving Average: $5.87
- 52-Week Range: $4.45 - $9.74
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -9.41
- P/E Growth: 0.00
- Market Cap: $880.89M
- Outstanding Shares: 130,496,000
- Beta: 1.47
- Net Margins: -2,276.89%
- Return on Equity: -364.49%
- Return on Assets: -32.89%
Companies Related to ZIOPHARM Oncology:
- Current Ratio: 7.35%
- Quick Ratio: 7.35%
What is ZIOPHARM Oncology's stock symbol?
ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."
Where is ZIOPHARM Oncology's stock going? Where will ZIOPHARM Oncology's stock price be in 2017?
5 brokers have issued twelve-month price targets for ZIOPHARM Oncology's shares. Their predictions range from $5.00 to $23.00. On average, they expect ZIOPHARM Oncology's stock price to reach $11.50 in the next year.
When will ZIOPHARM Oncology announce their earnings?
ZIOPHARM Oncology is scheduled to release their next quarterly earnings announcement on Monday, May, 8th 2017.
Who owns ZIOPHARM Oncology stock?
ZIOPHARM Oncology's stock is owned by a number of of institutional and retail investors. Top institutional investors include Third Security LLC (7.44%), State Street Corp (3.08%), MSD Partners L.P. (2.61%), Thrivent Financial for Lutherans (0.11%), Metropolitan Life Insurance Co. NY (0.07%) and Glacier Peak Capital LLC (0.05%).
Who sold ZIOPHARM Oncology stock? Who is selling ZIOPHARM Oncology stock?
ZIOPHARM Oncology's stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Brown Advisory Inc., Private Advisor Group LLC and Metropolitan Life Insurance Co. NY.
Who bought ZIOPHARM Oncology stock? Who is buying ZIOPHARM Oncology stock?
ZIOPHARM Oncology's stock was bought by a variety of institutional investors in the last quarter, including Third Security LLC, Glacier Peak Capital LLC, Michael & Susan Dell Foundation and National Planning Corp.
How do I buy ZIOPHARM Oncology stock?
Shares of ZIOPHARM Oncology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of ZIOPHARM Oncology stock cost?
One share of ZIOPHARM Oncology stock can currently be purchased for approximately $6.21.